Table 1.

Expression of SR-BI in cancer tissues or cell lines and its association with malignant features.

Type of cancer	Type of sample	Expression levels (compared to non-malignant tissue or cells)	Associated with	References
Adrenocortical carcinomas	Tissue	Decreased	ND	Liu et al., 1997
Testicular seminoma	Tissue	Decreased	ND	Arenas et al., 2004
Leydig cell tumor	Tissue	Increased	ND	Liu et al., 1997
Breast	Tissue	Increased	ND	Cao et al., 2004
Breast	Tissue	Increased	More aggressive tumor type	Yuan et al., 2016
Prostate	Tissue	Increased	Increased malignancy and androgen-independent growth	Schorghofer et al., 2015
Nasopharyngeal carcinoma	Tissue	Increased	ND	Zheng et al., 2013
Nasopharyngeal carcinoma	Cell line	Increased	Enhanced cell migration but not proliferation	Zheng et al., 2013
Breast	Cell line	NA	Enhanced proliferation	Cao et al., 2004
Breast	Cell line	NA	Enhanced proliferation and migration, and tumor growth in xenograft tumor model	Danilo et al., 2013
Prostate	Cell line	NA	PSA production and cell viability	Twiddy et al., 2012
Breast	PyMTTg mouse model	Increased	Tumor growth	Llaverias et al., 2011
Prostate	TRAMP mouse model	Increased	Tumor growth	Llaverias et al., 2010

ND, not determined; NA, not applicable.